Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid beta protein

Journal of Pharmacological Sciences

Volumn 95, Issue 2, 2004, Pages 248-255

  Hu, Jinfeng ^a   Geng, Meyu ^a   Li, Jing ^a   Xin, Xianliang ^a   Wang, Jia ^a   Tang, Minke ^b   Zhang, Juntian ^b   Zhang, Xiao ^c   Ding, Jian ^d  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Acidic oligosaccharide sugar chain; Aggregation; Amyloid beta protein; Neurotoxicity

Indexed keywords

ACIDIC OLIGOSACCHARIDE SUGAR CHAIN; AMYLOID BETA PROTEIN; NATURAL PRODUCT; OLIGOSACCHARIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALGA; ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG EFFECT; DRUG MECHANISM; ECHLONIA KUROME; FIBER; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN AGGREGATION; RAT; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

ECHLONIA KUROME;

EID: 3142548868     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FPJ04004X     Document Type: Article

References (30)

1. Castillo GM, Ngo C, Cumming J, Wight TN, Snow AD. Perlecan binds to the β-amyloid protein (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J Neurochem. 1997;69:2452-2465.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
3. Pallitto MM, Murphy RM. A mathematical model of the kinetics of β-amyloid fibril growth from the denatured state. Biophys J. 2001;81:1805-1822.
4. Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem. 1996;27:6839-6844.
5. Monji A, Utsumi H, Yoshida I, Hashioka S, Tashiro KI, Tashiro N. The relationship between Aβ-associated free radical generation and Aβ fibril formation revealed by negative stain electron microscopy and thioflavine T fluorometric assay. Neurosci Lett. 2001;304:65-68.
6. Mook-Jung I, Shin JE, Yun SH, et al. Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity. J Neurosci Res. 1999;58:417-425.
7. Cappai R, White AR. Amyloid β. Int J Biochem Cell Biol. 1999;31:885-889.
8. Walzer M, Lorens S, Hejna M, et al. Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology. Eur J Pharmacol. 2002;445:211-220.
9. Watson DJ, Lander AD, Selkoe DJ. Heparin-binding properties of the amyloidogenic peptide Aβ and amylin. J Biol Chem. 1997;272:31617-31624.
10. Mclaurin J, Fraser PE. Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur J Biochem. 2000;267:6353-6361.
11. Javier DN, Wandosell F, Avila J. Glycosaminoglycans and β-amyloid, prion and tau peptide in neurodegenerative disease. Peptides. 2002;23:1323-1332.
12. Fraser PE, Darabie AA, Mclaurin J. Amyloid-β interactions with chondroitin sulfate-derived monosaccharides and disaccharides. J Biol Chem. 2001;276:6411-6419.
13. Mclaurin J, Franklin T, Zhang XQ, Deng JP, Fraser PE. Interactions of Alzheimer's amyliod-β peptides with glycosaminoglycans (effect on fibril nucleation and growth). Eur J Biochem. 1999;266:1101-1110.
14. Leveugle B, Ding WH, Laurence F, et al. Heparin oligosaccharides that pass the blood-brain barrier inhibit β-amyloid precursor protein secretion and heparin binding to β-amyloid peptide. J Neurochem. 1998;70:736-744.
15. Cotman SL, Halfter W, Cole GJ. Agrin binds to β-amyloid (Aβ), accelerates Aβ fibril formation and is localized to Aβ deposits in Alzheimer's disease brain. Mol Cell Neurosci. 2000;15:183-198.
16. Polack SJ, Sadler IJ, Hawtin SR, Tailor VJ, Shearman MS. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells. Neurosci Lett. 1995;184:113-116.
17. Bergamaschini L, Donarini C, Rossi E, Luigi AD, Veregani C, Simoni MGD. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-β in vitro. Neurobiol Aging. 2002;23:531-536.
18. Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977;126:397-425.
19. Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther. 2000;88:93-113.
20. Ivins KJ, Ivins JK, Sharp JP, Cotman CW. Multiple pathways of apoptosis in PC12 cells. CrmA inhibits apoptosis induced by beta-amyloid. J Biol Chem. 1999;274:2107-2112.
21. Mattson MP. Centrol role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimer's disease review. 1997;2:1-14.
22. Fezou Y, Teplow DB. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem. 2002;277:36948-36954.
23. Cairo CW, Strzelec A, Murphy RM, Kiessling LL. Affinity-based inhibition of β-amyloid toxicity. Biochemistry. 2002;41:8620-8629.
24. Tabner BJ, Turnbull S, El-Agnaf OMA, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in alzheimer's disease and parkinson's disease. Free Radical Biol Med. 2002;32:1076-1083.
25. Allain H, Bentue-Ferrer D, Tribut O, Gauthier S, Michel BF, Drieu-La Rochelle C. Alzheimer's disease: the pharmacological pathway. Fundam Clin Pharmacol. 2003;17:419-428.
26. Eckert A, Keil U, Kressmann S, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry. 2003;36 Suppl 1:S15-S23.
27. Tony WC, Mcconlogue L, Kindy M, Schmidt AM. Key signaling pathways regulate the biological activities and accumulation of amyloid β. Neurobiol Aging. 2001;22:967-973.
28. Conlberg JA, Li J, Uversky VN, Fink AL. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synulcein in vitro. Biochemistry. 2002;41:1502-1511.
29. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301-323.
30. Martínez-Senac M, Villalaín J, Gómez- Fernández JC. Structure of the Alzheimer β-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur J Biochem. 1999;265:744-753.